319 related articles for article (PubMed ID: 21654267)
21. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Grabowski BA; Mayer MD; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2006 Jan; 46(1):88-102. PubMed ID: 16397288
[TBL] [Abstract][Full Text] [Related]
22. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
23. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
24. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
[TBL] [Abstract][Full Text] [Related]
26. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
27. Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Kim KA; Park JY
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):667-73. PubMed ID: 25997544
[TBL] [Abstract][Full Text] [Related]
28. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
[TBL] [Abstract][Full Text] [Related]
30. Febuxostat: drug review and update.
Grewal HK; Martinez JR; Espinoza LR
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):747-58. PubMed ID: 24684266
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
[TBL] [Abstract][Full Text] [Related]
32. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
33. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
34. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
35. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Hirai T; Kimura T; Echizen H
Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
[TBL] [Abstract][Full Text] [Related]
36. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
[TBL] [Abstract][Full Text] [Related]
37. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
38. Febuxostat for treatment of chronic gout.
Gray CL; Walters-Smith NE
Am J Health Syst Pharm; 2011 Mar; 68(5):389-98. PubMed ID: 21330679
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment.
Hira D; Chisaki Y; Noda S; Araki H; Uzu T; Maegawa H; Yano Y; Morita SY; Terada T
Pharmacology; 2015; 96(1-2):90-8. PubMed ID: 26183164
[TBL] [Abstract][Full Text] [Related]
40. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
